BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35653925)

  • 1. CRNDE inducing cisplatin resistance through SRSF1/TIA1 signaling pathway in ovarian cancer.
    Wu J; Ni X; Yu Z; Wu S; Liu Z
    Pathol Res Pract; 2022 Jul; 235():153957. PubMed ID: 35653925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Long Noncoding RNA CRNDE Increases Chemosensitivity of Medulloblastoma Cells by Targeting miR-29c-3p.
    Sun XH; Fan WJ; An ZJ; Sun Y
    Oncol Res; 2020 Feb; 28(1):95-102. PubMed ID: 31753063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA CRNDE promotes cell proliferation, migration and invasion of ovarian cancer via miR-423-5p/FSCN1 axis.
    Wang Q; Wang LX; Zhang CY; Bai N; Feng C; Zhang ZM; Wang L; Gao ZZ
    Mol Cell Biochem; 2022 May; 477(5):1477-1488. PubMed ID: 35166986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
    Wang DY; Li N; Cui YL
    Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
    Zhang C; Wang M; Shi C; Shi F; Pei C
    Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
    Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
    Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis.
    Long X; Song K; Hu H; Tian Q; Wang W; Dong Q; Yin X; Di W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):345. PubMed ID: 31391118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC.
    Li Z; Wu G; Li J; Wang Y; Ju X; Jiang W
    BMC Cancer; 2020 Apr; 20(1):282. PubMed ID: 32252678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
    Wu J; Zhang L; Wu S; Yi X; Liu Z
    Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
    Guo J; Pan H
    Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis.
    Miao JT; Gao JH; Chen YQ; Chen H; Meng HY; Lou G
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31189742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA EBIC promoted proliferation, metastasis and cisplatin resistance of ovarian cancer cells and predicted poor survival in ovarian cancer patients.
    Xu QF; Tang YX; Wang X
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4440-4447. PubMed ID: 30058681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transfer of LncRNA CRNDE in TAM-derived exosomes is linked with cisplatin resistance in gastric cancer.
    Xin L; Zhou LQ; Liu C; Zeng F; Yuan YW; Zhou Q; Li SH; Wu Y; Wang JL; Wu DZ; Lu H
    EMBO Rep; 2021 Dec; 22(12):e52124. PubMed ID: 34647680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Long Non-Coding RNA CRNDE Promotes Colorectal Carcinoma Progression by Competitively Binding miR-217 with TCF7L2 and Enhancing the Wnt/β-Catenin Signaling Pathway.
    Yu B; Ye X; Du Q; Zhu B; Zhai Q; Li XX
    Cell Physiol Biochem; 2017; 41(6):2489-2502. PubMed ID: 28472810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
    Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
    Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
    Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
    Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
    Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
    J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.